SLC5A2 and urinary tract infection: Patients using dapagliflozin have developed significant urinary tract infections, including pyelonephritis and urosepsis, requiring hospitalisation. Urinary tract infections are more prevalent when using SGLT2 inhibitors. Examine patients for signs of urinary tract infections and manage appropriately